Home  »  Companies   »  Is Now The Right Time To Buy Pliant Therapeutics I...

Is Now The Right Time To Buy Pliant Therapeutics Inc. (NASDAQ: PLRX) Stock?

Pliant Therapeutics Inc. (NASDAQ:PLRX) traded at $31.84 at last check on Tuesday, January 24, made an upward move of 5.15% on its previous day’s price.

Looking at the stock we see that its previous close was $30.28 and the beta (5Y monthly) reads 1.18 with the day’s price range being $29.94 – $36.50. In terms of its 52-week price range, PLRX has a high of $36.50 and a low of $3.96. The company’s stock has gained about 58.87% over that past 30 days.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Pliant Therapeutics Inc. has a market cap of $1.44 billion and is expected to release its quarterly earnings report on Feb 27, 2023 – Mar 03, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.74, with the EPS growth for the year raised at -$3.02 for 2022 and -$3.14 for next year. These figures represent -11.40% and -4.00% growth in EPS for the two years respectively.

The median projection represents growth adding up to -32.90% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $9.47 million, or 25.10% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the PLRX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 12 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Pliant Therapeutics Inc. (PLRX) stock as a Hold, while 11 rate it as a Buy. 1 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 53.41% off its SMA20 and 60.53% from its 50-day simple moving average. The RSI (14) is pointing at 84.49 while the volatility over the past week is 7.72% and jumps to 6.48% over the past one month. The average price target for the stock over the next 12 months is $47.36, with the estimates having a low of $36.00 and a high of $60.00. These price ends are -13.07% and -88.44% off the today’s price level respectively, although investors could be excited at the prospect of a -41.33% if the PLRX share price touches on the median price of $45.00.

Let’s briefly compare Pliant Therapeutics Inc. (PLRX) stock to its peers. We find that today’s price change of 5.15% and 170.36% over the past 12 months for PLRX competes that of AbbVie Inc. (ABBV), which has seen its stock price fall -1.16% in the latest trading session and is 11.67% over the last one year. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.40% and -0.23%, respectively, in early deals.

Coming back to Pliant Therapeutics Inc. (NASDAQ:PLRX), we note that the average 3-month trading volume was 620.15K, while that of the preceding 10-day period stands at 1.82 million. Current shares outstanding are 46.80 million.

The insiders hold 0.90% of the company’s shares while institutions hold 94.20%. The data shows that short shares as of Oct 13, 2022, stood at 3.77 million at a short ratio of 7.02. This represents a 7.74% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 3.16 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock 56.65% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.


We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam